Marinus pharmaceuticals inc (MRNS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Cash flows from operating activities
Net loss

-54,121

-36,726

-18,898

-28,643

-24,850

-

-

Net loss

-

-

-

-

-

-10,833

-5,270

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

278

127

126

23

11

-

-

Depreciation

-

-

-

-

-

5

10

Stock-based compensation expense

5,672

4,788

2,880

3,077

2,108

698

236

Amortization of discount on investments

-

-

-

-

2

-

-

Noncash interest on convertible notes payable

-

-

-

-

-

-

91

Change in fair value of warrant liability

-

-

-

-

-

-1,192

-153

Amortization of debt issuance costs

-

-

-

-

-

-4

-

Loss on disposal of fixed assets

-42

-

-

-

-

-

-

Noncash lease expense

225

-

-

-

-

-

-

Noncash lease liability

-131

-

-

-

-

-

-

Amortization of debt issuance costs

-

-

4

7

7

-

-

Amortization of discount on investments

8

79

28

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

1,480

237

779

-1,396

947

1,344

1,731

Accounts payable and accrued expenses

890

4,285

-2,121

-629

3,540

1,385

189

Net cash used in operating activities

-48,633

-27,842

-18,816

-24,769

-20,129

-

-

Net cash used in operating activities

-

-

-

-

-

-8,589

-6,628

Cash flows from investing activities
Maturities of short-term investments

6,994

20,000

3,922

4,474

1,743

-

-

Purchases of short-term investments

2,725

-

24,892

2,434

7,705

-

-

Purchases of property and equipment

388

83

450

644

352

33

-

Net cash provided by investing activities

3,881

19,917

-21,420

1,396

-6,314

-

-

Purchases of property and equipment

-

-

-

-

-

-

17

Net cash provided by investing activities

-

-

-

-

-

-33

-17

Cash flows from financing activities
Proceeds from exercise of stock options

97

14

96

124

373

128

18

Proceeds from equity offerings, net of offering costs

67,871

42,300

-

-

-

-

-

Principal payments of notes payable

-

-

5,247

2,128

-

-

-

Proceeds from public offerings, net of offering costs

-

-

-

-

-

41,202

-

Principal payments of notes payable

-

-

-

-

28,278

6,975

-

Proceeds from equity offerings, net of offering costs

-

-

52,547

-167

-206

-

-

Proceeds from short-term bank borrowings

-

-

193

-

-

-

-

Repayments of short-term bank borrowings

-

193

-

-

-

-

-

Proceeds from investor deposit

-

-

-

-

-

-

500

Proceeds from issuance of common stock, net of issuance costs

-

-

-

-

-

-

7,530

Net cash provided by/(used in) financing activities

67,968

42,121

47,589

-2,171

28,445

-

-

Net decrease in cash and cash equivalents

23,216

34,196

7,353

-25,544

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

2,002

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

48,305

8,048

Net decrease in cash and cash equivalents

-

-

-

-

-

39,683

1,403

Supplemental disclosure of cash flow information
Financing in accounts payable and accrued expenses

195

153

-

-

-

-

-

Cash paid for interest

-

-

184

460

468

-

-

Accrued equity offering costs

-

-

-

-

142

-

-

Conversion of preferred stock to common stock

-

-

-

-

-

70,340

-

Issuance of Series C Preferred Stock

-

-

-

-

-

500

-

Conversion of notes principal and accrued interest to preferred stock

-

-

-

-

-

-

2,761

Cash paid for interest

-

-

-

-

-

89

-

Financing arrangement with third-party vendor

-

-

-

-

584

-

-

Property and equipment in accounts payable and accrued expenses

-

-

-

134

-

-

-

Operating lease liability

3,357

-

-

-

-

-

-

Operating right-of-use asset

2,458

-

-

-

-

-

-